<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290120</url>
  </required_header>
  <id_info>
    <org_study_id>NILG 2009-012950-19</org_study_id>
    <nct_id>NCT01290120</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma</brief_title>
  <official_title>Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Italy Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern Italy Leukemia Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was set up to assess the efficacy and tolerability of a chemotherapy-immunotherapy
      combination programme originally introduced by GMALL (the German cooperative group for adult
      acute lymphoblastic leukemia)in 2002, to improve remission rate, overall and disease-free
      survival rates of adult patients with Burkitt's leukemia and lymphoma.

      The therapy includes a maximum of six chemotherapy courses (two with high doses of
      methotrexate and cytarabine) plus anti-CD20 antibody (Rituximab, up to 8 total doses),
      supplemented by local radiation therapy in the case of initial mediastinal or central nervous
      system (CNS) involvement or a residual tumor after chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cycle A1: prednisone-cyclophosphamide pre-phase (5 days), Rituximab on day 0, chemotherapy on
      days 1-5 (dexamethasone, iphosphamide, vincristine, high-dose methotrexate, triple
      intrathecal therapy).

      Cycle B1: Rituximab on day 0, chemotherapy on days 1-5 (dexamethasone, vincristine,
      cyclophosphamide, high-dose methotrexate, adriamycin, triple intrathecal therapy) Cycle C1:
      Rituximab on day 0, chemotherapy on days 1-5 (dexamethasone, vindesine, high-dose
      methotrexate, etoposide, high-dose cytarabine).

      Cycle A2: like cycle A1, without pre-phase. Cycle B2: like cycle B1. Cycle C2: like cycle C1.
      Cycle C2 is followed by two additional Rituximab injections.

      Notes:

        1. patients with stage I-II disease without mediastinal tumor or extranodal involvement
           receive only the first 4 cycles (A1 to A2).

        2. patients aged &gt;55 years do not receive cycles C (sequence: A1, B1, A2, B2, A3, B3 or A1,
           B1, A2, B2 if limited stage, with reduced-dose methotrexate).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients alive without disease at 5 years from date of diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients alive without disease at 5 years from date of remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of relapsed patients at 5 years from date of remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Percentage of patients achieving complete remission after the first two treatment cycles (defining the early response rate), and then confirmed to remain in complete remission at end of the six chemotherapy blocks. Re-staging procedures include physical examination, blood counts and biochemistry, bone marrow examination , and instrumental tests as appropriate (ultrasound scans, computed tomography, nuclear magnetic resonance, positron emission tomography)depending on clinical presentation of individual subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients who develop early and late therapy-related toxic side effects (including death in complete remision). Toxicity is defined according to the Common Toxicity Criteria scale (NCI), graded I-IV and referring to both hematological and extrahematologic toxicity. Early toxicity is registered during the first two chemotherapy cycles, and late toxicity following completion of therapy and up to 1 year from diagnosis.</description>
  </secondary_outcome>
  <enrollment type="Actual">182</enrollment>
  <condition>Burkitt Lymphoma</condition>
  <condition>B-ALL</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy-Rituximab combination</intervention_name>
    <description>Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.</description>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Vepesid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burkitt's leukemia or lymphoma (new diagnosis)

          -  Written informed consent

          -  Age &gt; 15 years

        Exclusion Criteria:

          -  pre-treated Burkitt's leukemia or lymphoma

          -  psychiatric disorders

          -  active second malignancy

          -  pregnancy

          -  absence of patient's written informed consent

          -  participation in other studies that interfere with the study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Ematologia Ospedali Riuniti di Bergamo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Ematologia e TMO, Ospedale San Maurizio</name>
      <address>
        <city>Bolzano</city>
        <state>(bz)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO - Ospedale Armando Businco</name>
      <address>
        <city>Cagliari</city>
        <state>(ca)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>(cn)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco-Ematologia - Ospedale Civile</name>
      <address>
        <city>Noale</city>
        <state>(ve)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Ematologia Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e TMO - Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - TMO - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Ematologia Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern Italy Leukemia Group</investigator_affiliation>
    <investigator_full_name>DR RENATO BASSAN</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Burkitt Lymphoma</keyword>
  <keyword>B-ALL</keyword>
  <keyword>Adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

